

- Abilify, 163
- Abrams, David, 270
- Abscesses, 53
- Abstinence syndrome, 93
- Abstinence violation effect (AVE), xvii, 19, 279, 291–292
- Abuse, 4–7, 9, 10
- Acceptance, spirituality and, 217–219
- Acetylcholine, 137, 138
- Acid. *See* Lysergic acid diethylamide (LSD)
- Acne, steroids and, 41
- Action paradigm, 254, 270
- Action stage, 257–258
RPT and, 296
- Activities of daily living (ADL), 164
- Acultural addict, 203–204
- Acupuncture, 75, 81
- Acute Stress Disorder, 176
- Adam. *See* Methylenedioxymethamphetamine (MDMA)
- Adderall, 187
- Addict, xvii, xviii
- Addiction:
biological basis of chemical, 34
culture of, xvi, 203–204
models of, 274–275
Addiction Professional, 235
- Addictive behavior model, 274, 275
- Administration, route of, 129
- Adolescent treatment, 75
- Adoption studies, 135–136
- Aerosols, 42. *See also* Inhalants
- Affective flattening, 161–162
- Against medical advice (AMA), 84
- Aggressiveness, steroids and, 41
- Agitation, alcohol abstinence syndrome and, 98, 99
- Agonists, 110–112
- Alanine transferase (ALT), 124
- Al-Anon, 246
- Alcohol:
addiction medications and, 132–134
assessing withdrawal potential, 98
tools for, 98–99
medical consequences of, 122
substance classifications and, 32
withdrawal syndrome
level of care, 101–102
pharmacologic treatment of, 102–103
sedative-hypnotic treatment, 103–105
symptoms, 99–100
- Alcoholics Anonymous (AA), xvii, xviii
founding of, 22, 79–80
motivation and, 18
spirituality and, 213–214
stages of change, 260–261
- Alcohol-induced liver disease (ALD), 123–124

- Alcohol Use Disorders Identification Test (AUDIT), 51, 55, 99
- Alcohol Use Inventory (AUI), 51
- Alogia, 162
- Amantadine, addiction medications and, 132
- Ambivalence, 19, 20–21, 276
 contemplation and, 256–257
 resolving, 265–267
- American Psychiatric Association (APA), 86
- American Society of Addiction Medicine (ASAM), xiv, 55–56, 71, 86, 94, 149
- Amphetamine, 27, 35. *See also* Stimulants
- Amyl nitrate, 42–43
- Amytal, 32
- Anabolic steroids, 41–42
- Anadrol, 41. *See also* Anabolic steroids
- Anesthesia, depressants and, 33
- Angel dust, 40. *See also* Phencyclidine (PCP)
- Anger management, 75
- Anorexia, alcohol abstinence syndrome and, 98
- Antabuse, 132–133
- Antagonists, 110–112
- Antidepressants, anxiety disorders and, 177
- Anti-Opium Bill, 27
- Antisocial Personality Disorder, 181
- Anxiety Disorders, xv, 139, 152
 Avoidant Personality Disorder and, 185
 psychoactive substances and, 11
- Aripiprazole, 163
- Aspartate, functions, 138
- Aspartate aminotransferase (AST), 124
- Asphyxiation, inhalants and, 43
- Assessment, 75
 applying tools, 61–67
 historical perspective, 47–48
 modern, 48–61
 overview, 67–69
- Associations, loosening of, 158, 159
- Ativan:
 anxiety disorders and, 177
 medical consequences of, 128
 substance classifications and, 32
- Attention-Deficit/Hyperactivity Disorder (ADHD), 35, 36, 132, 152, 186–188
- Atypical antidepressants, 168
- Auditory hallucinations, 159, 160
- Authentic power, 214
- Autobiography, RPT and, 284
- Aventyl, 168
- Aversion therapy, 277
- Avoidant Personality Disorder, 184–185
- Avolition, 162
- Baclofen, 132
- Balancing, 221
- Baldness, steroids and, 41
- Barbiturates, 27
 medical consequences of, 128
 substance classifications and, 32
 withdrawal and, 105
- Bean. *See* Methylenedioxymethamphetamine (MDMA)
- Behavioral change, counseling skills and, 251–254
 available resources, 267–269
 coping skills, 269–271
 preventing relapse, 271
 resolving ambivalence, 265–267
 stages-of-change strategies, 264–265
 understanding the stages of, 254–264
- BenGay, 31
- Bennies. *See* Amphetamine
- Benzodiazepines:
 medical consequences of, 128
 substance classifications and, 32
 treating anxiety disorders and, 177
 withdrawal and, 105
- Betty Ford Clinic, 202–203, 234–235
- Bibliotherapy, 167
- Bicultural addict, 203–204
- Binge drinking, 73

- Biomedical conditions, SUDs and, 119–120
- blood-borne diseases, 124
 - cardiovascular diseases, 121–123
 - chronic pain, 130–131
 - HIV/AIDS, 126–127
 - liver disease, 123–126
 - pulmonary and respiratory diseases, 128–129
 - renal damage, 130
 - tuberculosis, 129–130
 - viral hepatitis, 124–126
- Biopsychosocial assessment, 48
- Biopsychosocial influences, 10–13
- Biphetamine, 35
- Bipolar Disorder, 169–172
- Bizarre delusions, 159
- Black beauties. *See* Amphetamine
- Blood-alcohol concentration (BAC), 100
- Blood pressure, alcohol abstinence syndrome and, 98
- Blotter. *See* Lysergic acid diethylamide (LSD)
- Blunts, 40. *See also* Marijuana
- Bodybuilding. *See* Anabolic steroids
- Borderline features, 153
- Borderline Personality Disorder, 181–183
- Bradley, Nelson, 80, 85
- Breast development, steroids and, 41
- Breathalyzer readings, xv, 100
- Bup, 111
- Buprenorphine, 77
 - addiction medications and, 131
 - agonists and antagonists, 110
- Bupropion, 134, 168
- Buspirone, 134
- Butyl nitrate, 42
- Caffeine, 35–36. *See also* Stimulants
- Campral, 134
- Cancer, 130
- Cannabinoids, 39–40. *See also* Marijuana
- Carbamazepine, 171
- Cardiovascular diseases, xv
- Cat valiums, 41. *See also* Ketamine
- Catapres, 108
- Catatonic behavior, 159, 160, 162
- The Celestine Prophecy*, 224
- Center for Applied Sciences (CENAPS), 294, 296
- Center for Substance Abuse Treatment (CSAT), 16
- Central nervous system (CNS), psychoactive substances and, 4
- Chemically abusing mentally ill (CAMI), 150–151
- Child neglect, 53
- Childhood roles, 195–196
- Chloroform, 42. *See also* Inhalants
- Choking, inhalants and, 43
- Cibalith-S, 171
- Circumstantiality, 158, 159
- Clean time, 260–261
- Clinical Guide to Alcohol Treatment: The Community Reinforcement Approach*, 60
- Clinical Institute Withdrawal Assessment of Alcohol, revised (CIWA-Ar)*, 98–99, 100
- Clonidine, 131
 - opioid withdrawal and, 108
- Clozapine, 163
- Clozaril, 163
- Cocaine, 27, 35
 - addiction medications and, 132
 - dopamine and, 91, 92
 - medical consequences of, 129
 - neurochemicals and, 136–137
 - social strata and, 35
 - withdrawal and, 93
 - See also* Stimulants
- Cocaine Anonymous (CA), 21, 80
- Codeine, 38
 - detoxification and, 105
 - See also* Opioids
- Codependency, 75, 185–186
- Codependency Anonymous (CODA), 186
- Cognitive distortions, 280–281
- Cognitive therapy, 167–168

- Cognitive-Behavioral Coping Skills Therapy Manual: A Clinical Research Guide for Therapists Treating Individuals with Alcohol Abuse and Dependence*, 271
- Cognitive-behavioral therapy (CBT), anxiety disorders and, 177
- Collaboration, treatment planning and, 60
- College, drinking and drug use in, 73
- Coma:
 - depressants and, 33
 - PCP and, 40
- Committee to Frame a World Constitution, 227
- Community Reinforcement and Family Training (CRAFT), 246–248
- Comorbidity of Mental Disorders with Alcohol and Other Drug Abuse*, 149
- Comprehensive Drug Abuse Prevention and Control Act of 1970, 29
- Concealment, non-face-valid questioning and, 52–53
- Conduct Disorder, 139, 181
- Confessions of an English Opium Eater*, 3
- Confusion, steroids and, 41
- Contemplation, 256–257, 296
- Cooney, Ned, 270
- Coping skills:
 - RPT and, 278, 285–286
 - teaching, 269–271
- Cotter, Bruce, 197–198
- Counseling skills. *See* Behavioral change, counseling skills and
- Counselors, xviii
 - certified, 23
 - prerequisites, 24–25
- Couple therapy, 112
- Covey, Stephen, 252, 253
- Crack. *See* Cocaine
- Cranberry myth, 41
- Crank. *See* Methamphetamine
- Craving, 280, 281, 282
- Credibility:
 - assessment and, 47
 - training and, 49
- Crime:
 - arrests, 53
 - assessment and, 68
- Cronin, Patrick, 80
- Crystal meth. *See* Methamphetamine
- Culturally enmeshed addicts, 203–204
- Custody, loss of child, 53
- Cyclohexyl nitrate, 42
- Cyclothymic Disorder, 171
- Cylert, 187
- Darby's Carminative, 28
- Day hospital programs, xv, 71, 77
- Daytop, 16, 83
- Deca-Durabolin, 41. *See also* Anabolic steroids
- Dederich, Charles E., 16, 83
- Delinquency, assessment and, 68
- Delirium:
 - alcohol abstinence syndrome and, 98
 - ketamine and, 41
 - tremens (DTs), 99
 - withdrawal and, 34
- Delta-9-tetrahydrocannabinol (THC), 39–40. *See also* Marijuana
- Delusions:
 - alcohol abstinence syndrome and, 98
 - PCP and, 40
 - thinking and, 158, 159
- Dementia, withdrawal and, 34
- Demerol, 38. *See also* Opioids
- Denial, 281, 282
 - dual, 151
- Depakote, 171, 172
- Dependency, xvii, xviii, 4, 5, 7–8, 10, 17
- Dependent Personality Disorder, 185–186
- Depressants, 32–33
 - detoxification and, 97
 - medical consequences of, 128–129
 - stages of intoxication, 32
 - synergistic effect, 34
 - tolerance and withdrawal, 33–34
- Depression:
 - ketamine and, 41
 - psychoactive substances and, 11

- Depressive Disorder, Major, 165–167
 Avoidant Personality Disorder and, 185
 double, 167
- DeQuincey, Thomas, 3
- Designer drugs, 30
- Desipramine, 168
- Desoxyn, 187
- Desyrel, 168
- Detoxification, xv, 75, 93–94
 ambulatory, 95–96
 goals of, 94
 principles of, 94–95
 treatment levels, 95–97
 treatment protocols, 97–98
 agonists and antagonists, 110–112
 alcohol, 98–103
 methadone, 108–109
 nonpharmacological, 112–113
 opioids, 105–108, 109–110
 outpatient vs. inpatient, 113–114
 sedative hypnotics, 103–105
- Detoxification from Alcohol and Other
 Drugs*, 94, 98, 102, 103, 108
- Dex. *See* Amphetamine
- Dexedrine, 35, 187
- Diagnosis:
 differential, 157
 dual, 75, 150–151
See also Assessment
- Diagnostic and Statistical Manual of Mental
 Disorders, 4th edition, Text Revision (DSM-IV-TR)*, xvii, 8, 9,
 10, 86, 152
- Dialectical behavior therapy (DBT),
 183
- DiClemente, Carlo C., 254
- Dilaudid, 38. *See also* Opioids
- Discipline, spirituality and, 219
- Disease model, 14–15, 274
 Gorski RPT model and, 294
- Disinhibition, depressants and, 32–33
- Disorganized behavior, 159, 160, 162
- Dissociative anesthetics, 40–41
- Disulfiram, 132
- Dopamine, 90–92, 137–138
 homeostasis and, 93
 transporter, 91
- Dover's Powder, 28
- Dreaming, intense, 98
- Driving while ability impaired (DWAI),
 53
- Driving while intoxicated (DWI), 6, 53
- Dropout, early, 47
- Drug Abuse Screening Test (DAST), 51
- Drug abuser, xvii, xviii
- Drug Enforcement Administration
 (DEA), 29
- Drug-Free Workplace Act of 1988
 (DFWA), 205–206
- Durabolin, 41. *See also* Anabolic steroids
- Dysthymic disorder, 167
- E. *See* Methylenedioxymethampheta-
 mine (MDMA)
- Ecstasy, 29, 35
 Federal Analog Act of 1986 and, 30
 liquid, 32
 medical consequences of, 122
- Education:
 assessment and, 68
 classes, 112
- Effexor, 132, 168
- Ego, spirituality and, 213–217
- Electroconvulsive therapy (ECT), 167,
 169, 172
- Electrodermal reactivity, 140–141
- Electroencephalogram (EEG) measure-
 ments, 139
- Electrophysiological factors, 140–141
- Emotional states, negative, 277
- Empathy, 24–25, 252–253
 love as, 253–254
- Employee assistance program (EAP), 78
- Employment, 74
 assessment and, 68–69
- Enabling, 192
- Encounter groups, 83
- Encyclopedia Britannica*, 227
- Endorphins, 90, 137

- Enlightenment. *See* Spirituality
- Entheogens, 43
- Environment:
 drug-free social, 201–203
 family, xvi, 192–193
 social, 198–199
 work, 12, 204–206
- Epinephrine, 138
- Erotomanic delusion, 158, 159
- Eskalith, 171
- Ether, 42. *See also* Inhalants
- Ethyl alcohol. *See* Alcohol
- Euphoria, 36
- Event-related potentials (ERPs), 140
- Experimental use, 4–6
- Extended care, xv, 81–82
- Eye movement desensitization and re-processing (EMDR), 177–178
- Faces and Voices of Recovery, 202–203
- Face-valid approach, 49–52
 non-face-valid questioning, 52–55
- Family history, 67, 135–136, 193–194. *See also* Environment, family
- Family therapy, 75, 112
- Fatigue, steroids and, 41
- Fearing, James, 245
- Federal Analog Act of 1986, 30, 43
- Federal Department of Transportation, 74
Federal Register, 206
- Fentanyl, 38. *See also* Opioids
- Flashbacks, 39
- Flunitrazepam, 32
- Fluoxetine, 168
- Fluvoxamine. *See* Luvox
- Focus, dual, 150–151
- Ford, Betty. *See* Betty Ford Clinic
- Forgetfulness, steroids and, 41
- Forget-me pill, 32
The Four Agreements, 221
- Freebase. *See* Cocaine
- Funnel-down approach, 156–157
- G, 32
- Gabapentin, 171–172
- Gamma-aminobutyric acid (GABA),
 functions, 138
- Gamma-hydroxybutyrate (GHB), 32
- Gases, 42. *See also* Inhalants
- Gastrointestinal disorders, 53
- Gay 1890s, 28
- Gender, xviii, 17–18, 75
- Generalized Anxiety Disorder, 176
- Genetic influences, 17, 53, 135–141
- Geodon, 163
- Glaucoma, 40
- Global Assessment of Functioning
 (GAF), 156
- Glomerulosclerosis, 130
- Glutamate, 138
- Godfrey's Cordial, 28
- Gordon, Judith A., 273
- Gorski, Terence T., 294–297
- Grand mal seizures, 34, 98, 99
- Grandiose type, 158, 159
- Gratification, delaying, 220
- Group therapy, 112
- Gustatory hallucinations, 159, 160
- Halcion, 32
- Haldol, 163
- Halfway house, xv, 71, 82–83
- Hallucinations:
 alcohol abstinence syndrome and, 98,
 99
 PCP and, 40
 psychotic disorders and, 159–160
- Hallucinogens, 39
- Halothane, 42. *See also* Inhalants
- Hammer-heading, 29
- Harrison Narcotics Tax Act of 1914, 28
Harvard Mental Health Letter, 20
- Hashish, 39–40
- Hazelden, 80–81
- Heart attacks, steroids and, 41
- Hepatitis, xv, 53, 124–126
- Herman, Judith, 182
- Hero/heroine, 195
- Heroin, 27
 agonists and, 110

- determining dependence on, 50–51
- detoxification and, 105
- neurochemicals and, 137
- High school, drinking and drug use in, 72–73
- Higher power. *See* Spirituality
- High-risk situations, 276–278
- Histrionic Personality Disorder, 183–184
- Hitting bottom, myth of, xvi, 231
- HIV/AIDS, xv, 53, 125, 127–128
- Homeostasis, 93
 - family, 194–195
- Homosexuality, 75
- Hospitalization treatment, partial, 77–78
- Huffing, 12
- Humility, spirituality and, 213–217
- Hutchins, Robert Maynard, 227
- Hyperactivity, 139
- Hypodepressive disorder, 167
- Hypomanic episodes, 170–171

- Ice. *See* Methamphetamine
- If Life is a Game, These are the Rules*, 217
- I'll Quit Tomorrow*, 233
- Illicit drugs, 152
- Imipramine, 168
- Impulsivity, 138
- Individualization, 60, 75, 112
- Inhalants, 42–43
 - long-term effects of, 123
 - medical consequences of, 122–123
- Inpatient treatment programs, xv, 57–58, 78–84
 - detoxification and, 96–97, 113–114
 - medically managed intensive, 58, 75, 84–86
- Insomnia:
 - alcohol abstinence syndrome and, 98
 - steroids and, 41
- Inter-Care, 264
- Interferon, 126
- Intermittent Explosive Disorder, 152, 187, 188
- Interpersonal determinants, 277–278
- Interpersonal therapy, 167–168

- Intervention strategies:
 - early, 57, 72–75
 - structured, 231–232
 - history of, 232–235
 - models
 - CRAFT, 246–248
 - executive intervention, 245
 - Systematic Family Intervention, 244–245
 - Ten-Hour, 236–244
 - power of, 248–249
 - researching, 235–236
- Intoxication, biological understanding of, 90–92
- Intrapersonal determinants, 277
- Intuition. *See* Spirituality
- Irresponsibility, spirituality and, 219
- Isocarboxazid, 168

- Jealous type, 158, 159
- Johnson, Spencer, 221–222
- Johnson, Vernon E., 233, 234
- Johnson Institute, 233, 234, 244, 246
- Joints, 40. *See also* Marijuana
- Jone, Hendrée, 111
- Journal of Studies on Alcohol*, 73

- Kadden, Ronald, 270
- Ketamine, 40, 41

- LAAM (levo-alpha-acetylmethadol), 112, 131
- Lamictal, 171–172
- Lamotrigine, 171–172
- Lapses, 260
- Laughing gas, 42. *See also* Inhalants
- Leshner, Alan I., 127
- Letting go, 217–219
- Level of care (LOC), xv, 56–58
 - biomedical conditions and, 119–120
 - least restrictive, 75, 76
 - short-term goals, 59, 60
 - See also specific type*
- Lexapro, 132

- Librium:
 anxiety disorders and, 177
 substance classifications and, 32
 withdrawal and, 105
- Lifestyle imbalances, 280, 281
- Light therapy, 169
- Linehan, Marsha, 183–184
- Lithium, 171
- Lithobid, 171
- Lithonate, 171
- Liver disease, xv, 41, 53, 123–124
- Liver function test, 100–101
- Lost child, 195
- Low-dose dependencies, 5
- Lung cancer, xv
- Luvox:
 anxiety disorders and, 177
 depressive disorders and, 168
- Lysergic acid diethylamide (LSD), 27, 39, 137. *See also* Psychedelics
- M. *See* Methylenedioxymethamphetamine (MDMA)
- Maintenance, 259, 296
- Managed care companies (MCOs), 48
- Manic episodes, 169, 170
- Mapping, behavioral, 247
- Marijuana, 27, 39–40
 medical consequences of, 128
 neurochemicals and, 137
- Marijuana Anonymous (MA), 21
- Marlatt, Alan, 273
- Marplan, 168
- Mascot, 195
- Masculinization, 41
- Mather, Increase, 79
- McMunn's Elixir of Opium, 28
- Mecamylamine, 134
- Medication management, 75
- Medications, 67, 131–134. *See specific types*
- Mellaril, 163
- Memory impairment:
 alcohol abstinence syndrome and, 98
 cannabinoids and, 40
 depressants and, 33
 PCP and, 40
- Mental health history, assessment and, 67
- Mental illness, 149–151, 186–188
- Mentally ill chemical abuser (MICA), 150–151
- Mescaline, 39, 137. *See also* Psychedelics
- Methadone, xv, 38, 77
 addiction medications and, 130
 agonists and, 110, 111
 detoxification and, 105, 108–109
 opioid withdrawal and, 108–110
- Methamphetamine, 35
 medical consequences of, 129
See also Stimulants
- Methylenedioxymethamphetamine (MDMA), 30, 35. *See also* Ecstasy
- Methylphenidate, 35. *See also* Ritalin; Stimulants
- Michigan Alcoholism Screening Test (MAST), 50, 51, 55
- Microdot. *See* Lysergic acid diethylamide (LSD)
- Miller, William R., 260
- Minnesota model, 79–81
- Minnesota Multiphasic Personality Inventory (MMPI), 54, 55
- Mirtazapine, 168
- Mixed episodes, 169, 170
- Mixed personality disorder, 186
- Moderation management (MM), 200–201
- Monoamine oxidase inhibitors (MAOIs), 168, 177
- Monti, Peter, 270
- Mood Disorders, xv, 139, 152
- Mood swings, steroids and, 41
- Mood-altering substances. *See* Psychoactive substances
- Moral model, 14–15, 274
- Morphine, 28
 derivatives, 38
 detoxification and, 105

- Motivation, 18–20, 40
Motivational Interviewing: Preparing People for Change, 234, 253, 266, 267
 Mrs. Winslow's Soothing Syrup, 28
Multiaxial Evaluation Report Form, 153–156
- Multiple sclerosis, inhalants and, 43
 Muscle relaxation, depressants and, 33
- Naloxone, 110
 Naltrexone, 132–133
 addiction medications and, 131
 antagonists and, 110
 Nandrolone decanoate, 41. *See also* Anabolic steroids
 Nandrolone phenpropionate, 41. *See also* Anabolic steroids
 Narcissistic Personality Disorder, 184
 Narcolepsy, 36
 Narcotic Withdrawal Scale, 106–107
 Narcotics Anonymous (NA), 21, 80
 Nardil, 168
 National Cancer Institute (NCI), 36
 National Counseling Intervention Services, 245
 National Institute on Alcohol Abuse and Alcoholism (NIAA), 271
 National Institute on Drug Abuse (NIDA), 23, 31, 36, 90–92
 Nefazadone, 168
 Negative symptoms, 161
 Nembutal, 32
 Neuroadaptation, 93
 Neurochemicals, 136–139
 Neurontin, 171–172
 Neurotransmission, 90–92, 138, 139
 Nicotine, 36, 53
 addiction medications and, 134
 neurochemicals and, 137
 See also Stimulants
 NicVAX, 134
 Nitrates, 42–43. *See also* Inhalants
 Nitrous oxide, 42. *See also* Inhalants
 Noble experiment, 79
 Nonbizarre delusions, 159
 Norepinephrine, 138, 139
 Norpramine, 168
 North Brothers Island, 84
 Nortriptyline, 168
 Nucleus acumbens, 137
- Obesity, stimulants and, 36
 Obsessive Compulsive Disorder (OCD), 11, 175–176, 186
 Obsessive-Compulsive Personality Disorder, 176, 186
 Odyssey House, 16, 83
 Olanzapine, 163, 172
 Olfactory hallucinations, 159, 160
 One-upmanship, 24
 Openness, SUD professionals and, 25
 Opiates:
 addiction medications and, 131–132
 detoxification and, 97
 Opioid, 38
 detoxification and maintenance therapy, 105–108
 maintenance, xv, 77
 peptides, 138, 139
 substitution therapy, 109
 withdrawal and, 93
 Opium, 3, 28
 classification and importance, 30–31
 detoxification and, 105
 Organization skills, 25
 Outpatient treatment programs, 75–77
 ambivalence and, 19
 detoxification and, 113–114
 early intervention, 74–75
 intensive, xv, 57, 71, 77–78
 Overeaters Anonymous, 21
 Oxandrin, 41. *See also* Anabolic steroids
 Oxandrolone, 41. *See also* Anabolic steroids
 Oxford Group, 22
 Oxymetholone, 41. *See also* Anabolic steroids
- P3 Wave deficiencies, 140
 Pamelor, 168

- Pancreatitis, 53
- Panic Disorder, 173–174
- Paranoia, marijuana and, 40
- Paranoid Personality Disorder, 179–180
- Parkinson's disease, 132
- Parnate, 168
- Paroxetine. *See* Paxil
- Partial hospitalization, 57
- Patient Placement Criteria for the Treatment of Substance-Related Disorders*, 55, 57, 60–61, 86, 94, 95, 149
- Paxil, 168, 177
- Peck, M. Scott, 219, 253
- Pemoline. *See* Cylert
- Penal institutions, halfway houses and, 82
- People with substance abuse disorders (PSUDs), 15
- Percocet, 38, 105. *See also* Opioids
- Persecutory delusion, 158, 159
- Personal attribution effect, 279
- Personal status, 67
- Personality Disorders, xv, 152
- Person-in-environment, xvii
- Pertofrane, 168
- Pharmacotherapy, 168
- Phencyclidine (PCP), 40, 41
- Phenelzine, 168
- Phenobarbital, 32
- Phoenix House, 16, 58, 83
- Physician's Desk Reference*, xvii
- Pink cloud period, 20
- Pioneer House, 80
- Poppers. *See* Amyl nitrate
- Poppy, history of the, 38
- Positive outcome expectancies, 279
- Positive symptoms, 161
- Posttraumatic Stress Disorder (PTSD), 176
- Borderline Personality Disorder and, 182
- The Power of Now*, 216, 222
- The Precious Present*, 221–222
- Precontemplation, 255–256, 296
- Preparation, 257, 296
- Prevention, secondary. *See* Intervention, early
- Problematic substance use. *See* Abuse; Dependence
- Prochaska, James O., 254
- Prohibition, repeal of, 79–80
- Project R.E.T.U.R.N., 16, 83
- Prolapse, 292
- Prolixin, 163
- Propranolol, 132
- Prozac, 132
- anxiety disorders and, 177
- depressive disorders and, 168
- Psilocybin, 39. *See also* Psychedelics
- Psychedelics. *See* Hallucinogens
- Psychoactive substances, 4, 5
- classifications
- general, 31–43
- legal, 29–30
- history, 27–29
- Psychoeducation, 167
- Psychologist, xviii
- Psychophysiological factors, 139
- Psychotherapy, 75
- Psychotic Disorders, xv, 152
- Psychotic disturbance, withdrawal and, 34
- Psychotropic medications, 152
- Pulmonary disease, xv
- Pure Food and Drug Act of 1906, 28
- Quaalude, 105
- Quetiapine, 163, 172
- Quinlin, Karen Ann, 33, 34
- Rapport, 59
- Rationalization, 281, 282
- Recovery, 191–192, 206–208
- culture of addiction and, 203–204
- defined, 199–203
- early and advanced, 75
- family environment and, 192–196
- without a, 196–198
- four dimensions of, 199
- social environment and, 198–199
- workplace environment and, 204–206

- Recreational drug use, 4, 5–6
- Rehabilitation program, 79–81
- Rehabilitation, 39
- Relapse, 18, 259–260
increased risk of, 151–152
See also Relapse prevention therapy (RPT)
- Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors*, 273
- Relapse prevention therapy (RPT), xvii, 75, 271
framework, 273–282
strategies, 282–283
cognitive restructuring, 287–292
coping skills and, 285–287
Gorski model, 294–297
high-risk situations and, 283–285
lifestyle intervention, 292–294
- Relationships, assessment and, 67
- Reliability, 51
- Religious organizations, halfway houses and, 82
- Remeron, 168
- Residential rehabilitation program, 57–58, 71, 78–84, 96–97
- Residual type, 162
- Resistance:
dual, 151–152
spirituality and, 217–219
- Resources, assessment and, 69
- Resperidone, 163
- Respiratory problems, xv
cannabinoids and, 40
ketamine and, 41
- Responsibilities:
assessment and, 69
spirituality and accepting, 220–221
- ReVia, 110, 131, 134
- Reward pathway, 91, 92
- Ribavirin, 126
- Risperdol, 163
- Ritalin, 132, 187
- The Road Less Traveled*, 219, 220, 253
- Rohypnol, 32
- Roll. *See* Methylenedioxymethamphetamine (MDMA)
- Roofies, 32
- Ruiz, Don Miguel, 221
- Rush, Benjamin, 13
- Salvinorin A, 43
- Santayana, George, xiv
- Scapegoat, 195
- Schedule of drugs, 29–30
- Schizoid Personality Disorder, 180–181
Avoidant Personality Disorder and, 185
- Schizophrenia, 157, 158, 160–161
active or acute phase, 161
residual or stable phase, 161–162
- Seasonal affective disorder (SAD), 169
- The Seat of the Soul*, 214, 218
- Seconal:
substance classifications and, 32
withdrawal and, 105
- Sedative-hypnotic detoxification:
assessment issues, 103–104
LOC determination, 104–105
pharmacological treatment, 105
See also Depressants
- Seemingly irrelevant decisions (SIDs), 281, 282
- Seizures, PCP and, 40
- Selective serotonin reuptake inhibitors (SSRIs), 168
- Self-disclosure, 23–24
- Self-efficacy, 276, 284, 287–288
- Self-help group, 178
- Self-medication, 11, 137, 150
- Self-monitoring, 283–284
- Sensitivity, increased, 98
- Seroquel, 163, 172
- Serotonin, 138, 139
- Sertraline. *See* Zoloft
- Serum chemistry profile, 100–101
- Serum glutamic oxalacetic transaminase (SGOT), 124
- Serum glutamic pyruvate transaminase (SGPT), 124

- Serzone, 168
The 7 Habits of Highly Effective People, 252, 253
- Severity, SUD, 55–56
- Sex drive, steroids and, 41
- Sexually transmitted diseases (STDs), 53
- Shapiro, Francine, 177–178
- Sinusitis, 53
- Situational Competency Test (SCT), 286
- Situational Confidence Questionnaire (SCQ), 288
- Sleeping pills, withdrawal and, 105
- Smith, Robert Holbrook, 21, 22, 79–80
- Snappers. *See* Amyl nitrate
- Sobriety, xviii
- Social phobia, 175, 185
- Social pressure, 277
- Social support, lack of, 152
- Social worker, xviii
- Somatic hallucinations, 159, 160
- Specific Phobia, 174–175
- Specific serotonin reuptake inhibitors (SSRIs), 177
- Speech:
 PCP, 40
 poverty of, 158, 159
- Speed. *See* Methamphetamine
- Sperm, steroids and, 41
- Spicer, Jerry, 80–81
- Spirituality, xvi, 10–13, 14, 209–211, 226, 227
 acceptance versus resistance, 217–219
 dimensions of life, 212–213
 discipline versus irresponsibility, 219–221
 ego versus humility, 213–217
 explained, 211–212
 forgiveness, 226
 living in the moment, 221–223
 love, 226
- Spiritus Contra Spiritum*, 14
- Splitees, 84
- Stages of Change Readiness and Treatment Eagerness Scale* (SOCRATES), 260
- Step-down programs, 77–78
- Stimulants, 34–37
- Stress reduction programs, 75
- Strokes, steroids and, 41
- Student assistance programs (SAPs), 73
- Suboxone, 111
- Substance Abuse and Mental Health Services Administration (SAMHSA), 55, 109, 112
- Substance Abuse Subtle Screening Inventory (SASSI), 51–52, 54–55, 264, 265
 3rd Edition (SASSI-3), 55
- Substance P, 138
- Substance use disorders (SUDs), 3–4
 as a biological and spiritual disorder, 10–13
 defining, 8–9
 disease controversy and, 13–15
 professionals, 23–25
 progression of, 4–8
 providing evidence of, 49–55
 treatment (*see* Treatment)
- Substance Use Disorders Diagnostic Schedule (SUDDS), 51
- Subutex, 111
- Sudden sniffing death (SSD), 43, 122
- Suffocation, inhalants and, 43
- Suicide, higher risk of, 152
- Sunshine. *See* Lysergic acid diethylamide (LSD)
- Support systems, assessment and, 67
- Surprise party, 239
- Sweats, paroxysmal, 99
- Synanon, 16, 83, 84, 219
- Synapse, 91
- Synergistic effect, 34
- Systemic Family Intervention model, 244–245
- Tactile sensations, 98, 99
 hallucinations, 159, 160
- Tegretol, 171
- Temperature, elevated, 98
- Ten-Hour model, 236–244

- Termination, 260
- Testicles, steroids and, 41
- Testosterone levels, cannabinoids and, 40
- Therapeutic communities (TCs), xv, 16, 83–84
- Therapist, xviii
- Thorazine, 163
- Tobacco, 121–122, 128
- Tofranil, 168
- Tolerance:
 - characteristics of, 89
 - depressants and, 33–34
 - homeostasis and, 93
 - stimulants and, 37
- Topamax, 172
- Topiramate, 134, 172
- Trancyclopromine, 168
- Tranquilizers:
 - substance classifications and, 32
 - withdrawal and, 105
- Transtheoretical approach, 255
- Trauma, psychoactive substances and, 11
- Trauma and Recovery*, 182
- Trazadone, 168
- Treating Alcohol Dependence: A Coping Skills Training Guide*, 270, 286
- Treatment:
 - as a science, 15–16
 - effectiveness, 16
 - excessive, 77
 - goals of, 58–60
 - improper, assessment and, 47
 - introduction to, 114
 - misconceptions, 16–23
 - planning, 75 (*see also* Assessment)
 - readiness for, 69
 - rising costs, 48
- Treatment Improvement Protocol (TIP), 112
- Treatment of Opiate Addiction with Methadone: A Counselor Manual*, 109
- Triage Assessment for Addiction Disorders (TAAD), 51, 55
- Tricyclic antidepressants (TCAs), 168, 177
- Truth, dedication to, 221
- Tuberculosis, 129–130
- Tuinal, 32, 105
- 12-Step meetings, 21–23, 76
 - difficulty in, 152
 - reasons for success, 258–259
 - spirituality, 211
- Twin studies, 135–136
- U.S. Centers for Disease Control and Prevention (CDC), 124–125
- U.S. Department of Health and Human Services, 98
- U.S. Food and Drug Administration (FDA), 111, 131
- Ulcers, 53
- Unbundling, 60–61
- Understanding Drug Abuse and Addiction: What Science Says*, 90–92
- Undifferentiated type, 162
- University of Rhode Island Change Assessment (URICA)*, 260
- Uppers. *See* Amphetamine
- Validity, 51
- Valium:
 - anxiety disorders and, 177
 - medical consequences of, 128
 - substance classifications and, 32
 - withdrawal and, 105
- Valproate, 171
- Valproic acid, 171
- Venlafaxine, 168
- Ventral tegmental area (VTA), 91, 92
- Vesicles, 91
- Viagra, 29
- Vicodin, 105
- Videotherapy, 167
- Vigabatrin (GVG), 132
- Violence, PCP and, 40
- Visual hallucinations, 159, 160
- Volatile solvents, 42
- Weiner, Irving B., 168
- Wellbutrin, 135, 168

- When They Won't Quit: A Call to Action for Families, Friends, and Employers of Alcohol and Drug-Addicted People*, 197–198
- Willmar State Hospital, 80, 85
- Wilson, William Griffith, 21, 22, 79–80
- Withdrawal:
- characteristics of, 89–90
 - depressants and, 33–34
 - homeostasis and, 93
 - opioids and, 38
 - stimulants and, 37
- See also* Detoxification
- Workplace, use of drugs in, 28
- World Health Organization, 14, 212
- X. *See* Methylenedioxymethamphetamine (MDMA)
- Xanax, 173
- anxiety disorders and, 177
 - medical consequences of, 128
 - substance classifications and, 32
 - withdrawal and, 105
- XTC. *See* Methylenedioxymethamphetamine (MDMA)
- Yoga, 75
- hatha, 81
- Ziprasidone, 163
- Zoloft, 168, 177
- Zukav, Gary, 213–214
- Zyban, 134, 168
- Zyprexa, 163, 172